LEO Pharma announces positive top-line results for tralokinumab from three Phase 3 studies in adult patients with moderate-to-severe AD

met all primary and secondary endpoints in its three pivotal Phase 3 studies (ECZTRA 1-3) for the treatment of moderate-to-severe atopic dermatitis (AD) in adults. During the studies, the overall adverse event rate was comparable between tralokinumab and placebo.

IL-13 is a key driver of the type 2 inflammation that plays a major role in AD,¹ which is the most common inflammatory skin disease in the developed world,² affecting up to five percent of adults across the United States, Canada, Europe and Japan.³ AD can have a significant, negative impact on patients' well-being, primarily due to distressing itch, sleep deprivation and social stigmatization due to visible lesions.⁴

"In its moderate-to-severe form, AD can cause unbearable recurring symptoms for patients," said Dr Kim Kjoeller, Executive Vice President, Global Research & Development, LEO Pharma."Despite recent treatment advances, we consistently hear from healthcare professionals around the world that additional treatment options are needed to address the different signs and symptoms for each patient. We are encouraged by these study results, which show that tralokinumab could be an efficacious and well-tolerated long-term treatment solution for patients living with this debilitating chronic skin disease."

ECZTRA 1 and ECZTRA 2 (ECZema TRAlokinumab studies no. 1 and 2), are randomized, double-blind, placebo-controlled, multinational, 52-week studies, which included 802 and 794 adult patients respectively, to evaluate the efficacy and safety of tralokinumab as monotherapy in adults with moderate-to-severe AD who are candidates for systemic therapy. ECZTRA 3 is a randomized, double-blind, placebo-controlled, multinational 32-week study, which included 380 adult patients, to evaluate the efficacy and safety of tralokinumab in combination with topical corticosteroids (TCS) in patients with moderate-to-severe AD who are candidates for systemic therapy.

The primary endpoints in the three studies were an Investigator Global Assessment (IGA) score of clear (0) or almost clear (1) skin at week 16 and at least a 75 percent or greater change from baseline in their Eczema Area and Severity Index (EASI) score at week 16. A change from baseline to week 16 in SCORing of Atopic Dermatitis (SCORAD), Pruritus Numeric Rating Scale (NRS) of at least 4, and Dermatology Life Quality Index (DLQI) were secondary endpoints.

LEO Pharma is planning to submit marketing authorization applications for tralokinumab for the treatment of adult patients with moderate-to-severe AD to regulatory agencies in 2020 and plans to submit the detailed results of these studies for presentation at scientific congresses and publication in peer-reviewed medical journals in 2020 as well. Further information about trials with tralokinumab can be accessed at clinicaltrials.gov.

NOTES TO EDITORS

About atopic dermatitis

Atopic dermatitis (AD) is a chronic, relapsing skin disease, characterized by severe itch, dry skin, persistent immune-mediated inflammation, and skin barrier defects.⁵ AD is a result of skin barrier dysfunction and immune dysregulation, leading to chronic inflammation.⁶ Type-2 cytokines, such as IL-13 and IL-4, play a central role in the key aspects of AD pathophysiology.⁷ Due to the immune dysregulation, IL-13 is overexpressed in lesional and non-lesional skin.^8,9

About tralokinumab

Tralokinumab is an investigational agent under clinical development, and its safety and efficacy have not been evaluated by any regulatory authority. Tralokinumab is a fully human, immunoglobulin (Ig)G4 monoclonal antibody (mAb) that works by neutralizing the IL-13 cytokine. IL-13 plays a key role in the pathophysiology of AD.¹⁰  By specifically binding to the IL-13 cytokine, tralokinumab prevents its interaction with the receptor and the subsequent downstream IL-13 signalling.¹¹

References

1. Bieber T. Interleukin-13: Targeting an underestimated cytokine in atopic dermatitis. Allergy 2019; doi:10.111/all.13954.
2. Weidinger S et al. Atopic Dermatitis. Nat Rev Dis Primers 2018; 4(1):1.
3. Barbarot S et al. Epidemiology of atopic dermatitis in adults: Results from an international survey. Allergy 2018;73:1284-1293.
4. Weidinger S, Novak N. Atopic dermatitis. The Lancet. 2016; 387:1109-22.
5. Weidinger S, Novak N. Atopic dermatitis. The Lancet. 2016; 387:1109-22.
6. Boguniewicz M and Leung DY. Atopic dermatitis: a disease of altered skin barrier and immune dysregulation. Immunol Rev 2011 Jul;242(1):233-46.
7. Bieber T. Interleukin-13: Targeting an underestimated cytokine in atopic dermatitis. Allergy 2019; doi:10.111/all.13954.
8. Tsoi LC et al. Atopic dermatitis is an IL-13 dominant disease with greater molecular heterogeneity compared to psoriasis. J Invest Dermatol 2019 (Accepted Manuscript) https://doi.org/10.1016/j.jid.2018.12.018.
9. Tazawa T et al. Relative importance of IL-4 and IL-13 in lesional skin of atopic dermatitis. Arch Dermatol Res. 2004;295:459-464.
10. Brandt, E.B., Sivaprasad, U. Th2 Cytokines and Atopic Dermatitis. J Clin Cell Immunol. 2011; 2(3): 1-25. doi:10.4172/2155-9899.1000110.
11. Popovic B et al. Structural characterisation reveals mechanism of IL-13-neutralising monoclonal antibody tralokinumab as inhibition of binding to IL-13Rα1 and IL-13Rα2. J Mol Biol. 2017;429:208-219.